Comparative Pharmacology
Head-to-head clinical analysis: PEPCID RPD versus RANICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID RPD versus RANICLOR.
PEPCID RPD vs RANICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist